临床试验/NL-OMON45490

NL-OMON45490撤回不适用

An open-label, randomized, crossover study to evaluate the pharmacokinetics, bioavailability, and bioequivalence following administration of JZP-507 oral solution and Xyrem®in healthy subjects. - JZP-507 PK, BA and BE study.

Jazz Pharmaceuticals0 个研究点目标入组 60 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

阶段: 不适用
状态: 撤回
发起方: Jazz Pharmaceuticals
入组人数: 60

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 64（—）

入选标准

•Healthy male or female volunteers
•18 -45 years, inclusive
•BMI 20 -30 kg/m2, inclusive
•Weight minimum 60 kilogram
•non smokers

排除标准

•Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.

研究者

发起方

Jazz Pharmaceuticals

相似试验

进行中（未招募）

Patient preferences for Eucreas® versus Victoza® in Type 2 Diabetes mellitus patientstype 2 diabetes mellitusMedDRA version: 14.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disorders

EUCTR2011-003818-16-DEovartis Pharma GmbH

To estimate the bioavailability (amount of drug which reaches the blood) of GRC 17536 following oral administration in normal healthy male adults.

CTRI/2014/12/005320Glenmark Pharmaceuticals SA60

An open-label, randomized crossover study to evaluate the pharmacokinetics, bioavailability, bioequivalence, and food effect following administration of Oxybate Formulations in healthy subjects.

NL-OMON41817Jazz Pharmaceuticals60

An open-label, randomized crossover study to evaluate the effect of ASP1941 on the pharmacokinetics, pharmacodynamics, safety and tolerability of glimepiride in healthy subjects and vice versa.

NL-OMON34715Astellas Pharma26

A randomized, open-label, crossover study to evaluate ICS/LABA treatment versus LAMA/LABA treatment in COPD with eosinophilic inflammatioCOPD

JPRN-UMIN000024905Department of Respiratory Medicine, Japanese Red Cross Ishinomaki Hospital25